Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Relugolix May Become New Standard of Care for Advanced Prostate Cancer

TON - August 2020, Vol 13, No 4 - Prostate Cancer
Patricia Stewart

Oral relugolix given daily is superior to standard an­drogen-­deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting (Shore ND, et al. N Engl J Med. 2020;382:2187-2196).

Almost all (96.7%) the men who received ADT with relugolix maintained castrate levels of testosterone through 48 weeks (the primary end point) versus 88% of men who received ADT with leuprolide (P <.001 for superiority). Of note, major cardiac events were cut by 54% with relugolix treatment.

In June 2020, the FDA granted a priority review for relugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer.

ADT with leuprolide acetate, a luteinizing hormone-releasing hormone agonist, is administered as an injection and is associated with increased risk for major cardiac events, including myocardial infarction, sudden cardiac death, and stroke; the new oral GnRH therapy reduces the risk for those events substantially.

Approximately 30% of men with prostate cancer have cardiovascular disease, and 90% of those enrolled in the HERO study had cardiac risk factors.

“In the HERO trial, the oral GnRH antagonist relugolix showed sustained testosterone suppression superior to that of leuprolide and resulted in a 54% lower risk of major cardiovascular events than with ­leuprolide,” stated lead investigator Neal D. Shore, MD, FACS, Director, Carolina Urologic Research Center, Myrtle Beach, SC.

Potential New Standard of Care

“Relugolix is a novel oral GnRH antagonist that has the potential to become a new standard for ADT in advanced prostate cancer.”

The global phase 3 HERO trial randomized 930 men with advanced prostate cancer in a 2:1 ratio to oral relugolix 120 mg daily (N = 622) or to leuprolide injections (N = 308) every 3 months for a total of 48 weeks. Eligible patients had either evidence of biochemical or clinical relapse after primary therapy with curative intent, newly diagnosed hormone-sensitive metastatic disease, or advanced localized disease that is unlikely to be cured. Patients who had major cardiac events within 6 months of enrollment were excluded.

At baseline, approximately 31% of the patients (median age, 71 years) had metastatic disease, 43% had a Gleason score of 8 to 10, 11.9% had previous ADT, and 30.3% had previous radiotherapy. The median prostate-specific antigen (PSA) level at baseline was 10.8 ng/mL, and the mean testosterone level at baseline was 427.5 ng/dL. The median time to follow-up, including safety, was 52 weeks.

Relugolix met the primary end point of the trial and was superior to leuprolide for all key secondary end points (P <.001). The percentage of patients with a confirmed PSA response at day 15 was 79.4% with relugolix versus 19.8% with leuprolide (P <.001).

Men who received treatment with relugolix achieved castrate levels of testosterone more rapidly than the patients who received leuprolide, and these levels were maintained throughout treatment.

Adverse Events

The overall incidence of adverse events was consistent across the 2 treatment arms. Hot flash was the most common adverse event in both arms, at 54.3% for relugolix and 51.6% for leuprolide. Mild or moderate diarrhea was reported in more patients in the relugolix group than in the leuprolide cohort (12.2% vs 6.8%, respectively). There were no treatment withdrawals because of diarrhea.

The mortality rate was 1.1% in the relugolix group and 2.9% in the leuprolide group.

In a prespecified analysis of patients who received 48 weeks of treatment, the incidence of major cardiac events was 2.9% in the relugolix group compared with 6.2% in the leuprolide group, which was 54% lower than with the oral ADT. An even more striking advantage of treatment with relugolix was seen in patients with a reported history of major cardiac events; the incidence of major cardiac events during treatment was 3.6% for relugolix and 17.8% for leuprolide.

“The odds were 4.8 times higher with leuprolide as with relugolix in men with a history of MACE [major cardiac events],” Dr Shore stated.

Practice-Changing Results

David R. Wise, MD, PhD, Attending Physician, Genitourinary Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, who discussed this study, called oral ADT a new standard of care.

“Is this practice-changing? Yes, for a subset of patients with a history of significant cardiovascular disease and without gastrointestinal malabsorption problems. I will use this drug to avoid injection-site reactions commonly experienced with degarelix,” Dr Wise emphasized. Degarelix is another injectable GnRH receptor antagonist.

“The concern for noncompliance with an oral drug will necessitate more frequent serum testosterone checks, particularly for monotherapy,” he concluded.

Related Items
Addition of Copanlisib to Rituximab Improves Outcomes in Indolent NHL
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in AACR Highlights
Selpercatinib Demonstrates Encouraging Activity in a Range of RET Fusion–Positive Solid Tumors
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in AACR Highlights
Study Identifies Inherited Pathogenic Germline Variants in Pediatric Neuroblastoma
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in AACR Highlights
Becoming Pregnant Is Feasible But Less Likely for Breast Cancer Survivors
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Survivorship
Current and Future Effects of the COVID-19 Pandemic on Cancer Care
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in COVID-19
Enfortumab Vedotin Prolongs Survival in Patients with Metastatic Urothelial Cancer
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Urothelial Cancer
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Prostate Cancer
Many Postmenopausal Women with HR-Positive, HER2-Negative, Early-Stage Breast Cancer May Be Able to Skip Additional Chemotherapy
Patricia Stewart
TON - April 2021 Vol 14, No 2 published on April 19, 2021 in Breast Cancer
Promising Results Seen with Ruxolitinib as Second-Line Treatment for Chronic GVHD
Patricia Stewart
TON - April 2021 Vol 14, No 2 published on April 19, 2021 in Hematologic Malignancies
Fixed-Duration Ibrutinib plus Venetoclax Regimen Promising as First-Line Treatment in CLL
Patricia Stewart
TON - April 2021 Vol 14, No 2 published on April 19, 2021 in Hematologic Malignancies
Last modified: July 22, 2021